The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
BRAF Mutations in Hairy-Cell Leukemia
Open accessAbstract
BACKGROUND: Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure. METHODS: We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL. RESULTS: Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. CONCLUSIONS; The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,433
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,422
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Genetic diagnosis by whole exome capture and massively parallel DNA sequencing
Choi, M., Scholl, U. I., Ji, W., Liu, T., Tikhonova, I. R., Zumbo, P., Nayir, A., Bakkaloğlu, A., Özen, S., Sanjad, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910672106 · Cited by 1,329
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Campbell, P. J., Stephens, P. J., Pleasance, E. D., O'Meara, S., Li, H., Santarius, T., Stebbings, L. A., Leroy, C., Edkins, S., Hardy, C., et al. (2008) · Nature Genetics · doi:10.1038/ng.128 · Cited by 824
Keshet, Y., & Seger, R. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-795-2_1 · Cited by 642
Genetic Variation in an Individual Human Exome
Ng, P. C., Levy, S., Huang, J., Stockwell, T. B., Walenz, B. P., Li, K., Axelrod, N., Busam, D. A., Strausberg, R. L., & Venter, J. C. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000160 · Cited by 291
BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Falini, B., Tiacci, E., Liso, A., Basso, K., Sabattini, E., Pacini, R., Foa, R., Pulsoni, A., Favera, R. D., & Pileri, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16356-3 · Cited by 244
Self-citationTie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25555 · Cited by 227
Roovers, K., Davey, G., Zhu, X., Bottazzi, M. E., & Assoian, R. K. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.10.3197 · Cited by 212
Basso, K., Liso, A., Tiacci, E., Benedetti, R., Pulsoni, A., Foa, R., Di Raimondo, F., Ambrosetti, A., Califano, A., Klein, U., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031175 · Cited by 206
Self-citationSala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E., & Gambacorti-Passerini, C. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2001 · Cited by 188
BRAF as therapeutic target in melanoma
Wellbrock, C., & Hurlstone, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.019 · Cited by 178
Targets of Raf in tumorigenesis
Niault, T., & Baccarini, M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp337 · Cited by 157
Bhatt, K. V., Spofford, L. S., Aram, G., McMullen, M. E., Pumiglia, K. M., & Aplin, A. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208544 · Cited by 153
Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia
Case, M. C., Matheson, E. C., Minto, L., Hassan, R., Harrison, C. J., Bown, N. P., Bailey, S., Vormoor, J. H., Hall, A. G., & Irving, J. A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0101 · Cited by 138
Evolving concepts in the pathogenesis of hairy-cell leukaemia
Tiacci, E., Liso, A., Piris, M. A., & Falini, B. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1888 · Cited by 106
Self-citationBhatt, K., Hu, R., Spofford, L. S., & Aplin, A. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209861 · Cited by 70
BRAF mutations in non-Hodgkin's lymphoma
Lee, J. W., Yoo, N. J., Soung, Y. H., Kim, H. S., Park, W. S., Kim, S. Y., Lee, J. H., Park, J. Y., Cho, Y. G., Kim, C. J., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601371 · Cited by 68
Kamiguti, A. S., Harris, R. J., Slupsky, J. R., Baker, P. K., Cawley, J. C., & Zuzel, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206398 · Cited by 54
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia
Gustafsson, B. M., Angelini, S., Sander, B., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403589 · Cited by 46
Nicolaou, F., Teodoridis, J. M., Park, H., Georgakis, A., Farokhzad, O. C., Böttinger, E. P., Da Silva, N., Rousselot, P., Chomienne, C., Ferenczi, K., et al. (2003) · Blood · doi:10.1182/blood-2002-01-0324 · Cited by 39
Targeting of the BRAF gene in papillary thyroid carcinoma (Review)
Kakudo (2009) · Oncology Reports · doi:10.3892/or_00000487 · Cited by 33
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia
Chilosi, M., Chiarle, R., Lestani, M., Menestrina, F., Montagna, L., Ambrosetti, A., Prolla, G., Pizzolo, G., Doglioni, C., Piva, R., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02210.x · Cited by 28
Self-citationBRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias
Davidsson, J., Lilljebjörn, H., Panagopoulos, I., Fioretos, T., & Johansson, B. (2008) · Leukemia · doi:10.1038/leu.2008.14 · Cited by 25
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
“(%) 2 (11) 5 (50) 7 (27) 3 (38) 0 4 (57)”
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., Sportoletti, P., Pettirossi, V., Mannucci, R., Elliott, O., Liso, A., Ambrosetti, A., Pulsoni, A., Forconi, F., Trentin, L., Semenzato, G., Inghirami, G., Capponi, M., Di Raimondo, F., Patti, C., Arcaini, L., Musto, P., Pileri, S., Haferlach, C., Schnittger, S., Pizzolo, G., Foà, R., Farinelli, L., Haferlach, T., Pasqualucci, L., Rabadan, R., & Falini, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-16
- Volume
- 364
- Issue
- 24
- Pages
- 2305-2315
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2099780734
- Cited by
- 1,024
- References
- 34
- FWCI
- 48.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.